TARS Valuation

Tarsus Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

56.560

+1.15(2.075%)1D

Overview
Forecast
Valuation
Earnings

TARS Relative Valuation

TARS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TARS is overvalued; if below, it's undervalued.

Historical Valuation

Tarsus Pharmaceuticals Inc (TARS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.21 is considered Undervalued compared with the five-year average of -17.68. The fair price of Tarsus Pharmaceuticals Inc (TARS) is between 82.27 to 373.95 according to relative valuation methord. Compared to the current price of 56.56 USD , Tarsus Pharmaceuticals Inc is Undervalued By 31.25%.

Relative Value

Fair Zone

82.27-373.95

Current Price：56.56

31.25%

Undervalued

-207.90

Trailing

Forward

59.67

EV/EBITDA

Tarsus Pharmaceuticals Inc. (TARS) has a current EV/EBITDA of 59.67. The 5-year average EV/EBITDA is -0.56. The thresholds are as follows: Strongly Undervalued below -81.35, Undervalued between -81.35 and -40.96, Fairly Valued between 39.83 and -40.96, Overvalued between 39.83 and 80.22, and Strongly Overvalued above 80.22. The current Forward EV/EBITDA of 59.67 falls within the Overvalued range.

-247.03

EV/EBIT

Tarsus Pharmaceuticals Inc. (TARS) has a current EV/EBIT of -247.03. The 5-year average EV/EBIT is -15.10. The thresholds are as follows: Strongly Undervalued below -80.00, Undervalued between -80.00 and -47.55, Fairly Valued between 17.35 and -47.55, Overvalued between 17.35 and 49.79, and Strongly Overvalued above 49.79. The current Forward EV/EBIT of -247.03 falls within the Strongly Undervalued range.

4.21

Tarsus Pharmaceuticals Inc. (TARS) has a current PS of 4.21. The 5-year average PS is 18.55. The thresholds are as follows: Strongly Undervalued below -8.60, Undervalued between -8.60 and 4.98, Fairly Valued between 32.12 and 4.98, Overvalued between 32.12 and 45.70, and Strongly Overvalued above 45.70. The current Forward PS of 4.21 falls within the Undervalued range.

0.00

P/OCF

Tarsus Pharmaceuticals Inc. (TARS) has a current P/OCF of 0.00. The 5-year average P/OCF is -26.85. The thresholds are as follows: Strongly Undervalued below -197.66, Undervalued between -197.66 and -112.25, Fairly Valued between 58.56 and -112.25, Overvalued between 58.56 and 143.97, and Strongly Overvalued above 143.97. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Tarsus Pharmaceuticals Inc. (TARS) has a current P/FCF of 0.00. The 5-year average P/FCF is 32.89. The thresholds are as follows: Strongly Undervalued below -303.99, Undervalued between -303.99 and -135.55, Fairly Valued between 201.33 and -135.55, Overvalued between 201.33 and 369.77, and Strongly Overvalued above 369.77. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Tarsus Pharmaceuticals Inc (TARS) has a current Price-to-Book (P/B) ratio of 6.81. Compared to its 3-year average P/B ratio of 4.29 , the current P/B ratio is approximately 58.81% higher. Relative to its 5-year average P/B ratio of 3.44, the current P/B ratio is about 98.17% higher. Tarsus Pharmaceuticals Inc (TARS) has a Forward Free Cash Flow (FCF) yield of approximately -3.59%. Compared to its 3-year average FCF yield of -10.45%, the current FCF yield is approximately -65.63% lower. Relative to its 5-year average FCF yield of -7.11% , the current FCF yield is about -49.46% lower.

6.81

P/B

Median3y

4.29

Median5y

3.44

-3.59

FCF Yield

Median3y

-10.45

Median5y

-7.11

Competitors Valuation Multiple

The average P/S ratio for TARS's competitors is 9.32, providing a benchmark for relative valuation. Tarsus Pharmaceuticals Inc Corp (TARS) exhibits a P/S ratio of 4.21, which is -54.80% above the industry average. Given its robust revenue growth of 151.54%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

TARS.O

Tarsus Pharmaceuticals Inc

Amicus Therapeutics Inc

Ocular Therapeutix Inc

Supernus Pharmaceuticals Inc

Performance Decomposition

Market capitalization of TARS increased by 108.63% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 40.81M to 102.66M.

The secondary factor is the P/E Change, contributed 32.80%to the performance.

Overall, the performance of TARS in the past 1 year is driven by Revenue Growth. Which is more sustainable.

151.54%

40.81M → 102.66M

Revenue Growth

-75.71%

-81.57 → -19.81

Margin Expansion

32.80%

-18.04 → -23.96

P/E Change

108.63%